The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor α

被引:222
|
作者
Miyake, S
Lupher, ML
Druker, B
Band, H
机构
[1] Harvard Univ, Brigham & Womens Hosp,Sch Med, Dept Med,Div Rheumatol Immunol & Allergy, Lymphocyte Biol Sect, Boston, MA 02115 USA
[2] Oregon Hlth Sci Univ, Div Haematol & med Oncol, Portland, OR 97201 USA
关键词
D O I
10.1073/pnas.95.14.7927
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The Cbl protooncogene product has emerged as a negative regulator of receptor and nonreceptor tyrosine kinases, We recently demonstrated that oncogenic Chl mutants upregulate the endogenous tyrosine kinase signaling machinery when expressed in the NIH 3T3 cells, and identified the platelet-derived growth factor receptor-alpha (PDGFR alpha) as one of the tyrosine kinases targeted by these oncogenes. These findings suggested a role for the normal Cbl protein in negative regulation of the PDGFR alpha. However, the mechanism of such negative regulation remained to be determined. Here we show that overexpression of the wild-type Cbl enhances the ligand-induced ubiquitination of the PDGFR alpha. Concomitantly, the PDGPR alpha in Cbl-overexpressing cells undergoes a faster ligand-induced degradation compared with that in the control cells. These results identify a role for Cbl in the regulation of ligand-induced ubiquitination and degradation of receptor tyrosine kinases and suggest one potential mechanism for evolutionarily conserved negative regulatory influence of Cbl on tyrosine kinases.
引用
收藏
页码:7927 / 7932
页数:6
相关论文
共 50 条
  • [1] The tyrosine kinase regulator Cbl enhances the ligand-dependent ubiquitination and degradation of the platelet-derived growth factor receptor.
    Miyake, S
    Mullane, KP
    Band, H
    [J]. MOLECULAR BIOLOGY OF THE CELL, 1998, 9 : 342A - 342A
  • [2] Inhibitors of the platelet-derived growth factor receptor tyrosine kinase
    Bilder, GE
    Rojas, CJ
    [J]. CARDIOVASCULAR DRUG REVIEWS, 1996, 14 (04): : 380 - 399
  • [3] A potent inhibitor of platelet-derived growth factor receptor tyrosine kinase
    Min, DS
    Lee, YH
    Kang, LW
    Byoun, CH
    Chang, JS
    Ryn, SH
    Suh, PG
    [J]. MOLECULES AND CELLS, 1996, 6 (04) : 463 - 468
  • [4] PLATELET-DERIVED GROWTH-FACTOR TYROSINE KINASE RECEPTOR-MEDIATED PROLIFERATION
    BENITO, M
    LORENZO, M
    [J]. GROWTH REGULATION, 1993, 3 (03): : 172 - 179
  • [5] PREFERENTIAL INHIBITION OF THE PLATELET-DERIVED GROWTH-FACTOR RECEPTOR TYROSINE KINASE BY STAUROSPORINE
    SECRIST, JP
    SEHGAL, I
    POWIS, G
    ABRAHAM, RT
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1990, 265 (33) : 20394 - 20400
  • [6] Inhibition of platelet-derived growth factor receptor tyrosine kinase by atrial natriuretic peptide
    Awazu, M
    [J]. KIDNEY INTERNATIONAL, 1997, 52 (02) : 356 - 362
  • [7] Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature
    Dai, Yujia
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2010, 20 (07) : 885 - 907
  • [8] In vitro characterization of a novel series of platelet-derived growth factor receptor tyrosine kinase inhibitors
    Sawutz, DG
    Bode, DC
    Briggs, GM
    Reid, JR
    Canniff, P
    Caldwell, L
    Faltynek, CR
    Miller, D
    Dunn, JA
    deGaravilla, L
    Guiles, JW
    Weigelt, C
    Michne, W
    Treasurywala, AM
    Silver, PJ
    [J]. BIOCHEMICAL PHARMACOLOGY, 1996, 51 (12) : 1631 - 1638
  • [9] PLATELET-DERIVED GROWTH-FACTOR RECEPTOR BIOSYNTHESIS AND DEGRADATION
    KEATING, MT
    WILLIAMS, LT
    [J]. CIRCULATION, 1987, 76 (04) : 243 - 243
  • [10] THE PLATELET-DERIVED GROWTH-FACTOR RECEPTOR IS PHYSICALLY ASSOCIATED WITH A PLATELET-DERIVED GROWTH FACTOR-SENSITIVE PHOSPHATIDYLINOSITOL KINASE
    COUGHLIN, SR
    ESCOBEDO, JA
    WILLIAMS, LT
    [J]. CLINICAL RESEARCH, 1988, 36 (03): : A270 - A270